Publications by authors named "M Watabe"
For patients with advanced heart failure, palliative care, including opioids, is needed as a treatment for refractory dyspnea. However, little evidence has been reported on the efficacy and safety of opioids, and their use is not well established. We have introduced a protocol for the use of opioids for dyspnea in patients with advanced heart failure admitted to Saitama Citizens Medical Center.
View Article and Find Full Text PDFWe investigated the gastric and esophageal cancer cases treated with immune checkpoint inhibitors and chemotherapy at our hospital. Out of 17 gastric cancer cases, 9 were treated with nivolumab(Nivo)plus S-1/oxaliplatin(SOX), 5 with Nivo plus 5-fluorouracil/Leucovorin/oxaliplatin(FOLFOX), and 3 with Nivo plus capecitabine/oxaliplatin(CapeOX), yielding a response rate of 35.3%.
View Article and Find Full Text PDFArticle Synopsis
- * It analyzed data from 155 patients, using muscle and body fat measurements to define sarcopenia and obesity, finding that 16.8% had both conditions (sarcopenic obesity).
- * Results showed that patients with sarcopenic obesity faced significantly more severe postoperative complications compared to those without it, indicating it as an independent risk factor.
Article Synopsis
- The study investigated the characteristics of α-fetoprotein (AFP)-producing gastric carcinoma (AFP-GC) with a focus on its association with HER2 overexpression to enhance treatment strategies.
- A total of 41 patients were analyzed for serum AFP levels and HER2 expression using immunohistochemistry and fluorescence in situ hybridization techniques.
- Results indicated that 17.1% of the patients had HER2 overexpressed AFP-GC, which was linked to a heterogeneous histology and mixed-type tumors; these mixed-type tumors showed a trend towards better clinical outcomes compared to other types.
FDI-6, a FOXM1 inhibitor, activates the aryl hydrocarbon receptor and suppresses tumorsphere formation.
Biochem Biophys Res Commun
January 2023
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that is activated by environmental contaminants such as dioxins and polycyclic aromatic hydrocarbons. Following ligand binding, AhR binds to xenobiotic responsive elements and modulates the transcription of AhR target genes. Multiple studies have shown that AhR plays important roles in a range of cancer cells and is attracting attention as a therapeutic target for cancer treatment.
View Article and Find Full Text PDF